Metastatic Esophageal Carcinoma | Norton Healthcare

Indication: Metastatic Esophageal Carcinoma

A Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) + Lenvatinib (E7080/MK-7902) + Chemotherapy Compared with Standard of Care as First-line Intervention in Participants with Metastatic Esophageal Carcinoma

Sub-indication: Gastrointestinal Cancer

Study Type: Drug Study

Principal Investigator: Michael Driscoll, M.D.
Norton Cancer Institute

Sponsor: Sponsor: Merck Sharp & Dohme CORP

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.